L'Oréal USA S/D Inc is defending a proposed consumer class action filed in the US District Court for the Southern District of California, in which a California shopper alleges that certain CeraVe Baby products are sold at a premium despite being, in substance, the same as their standard CeraVe counterparts. The complaint, brought by named plaintiff Monica Raymundo and lodged under case number 3:26-cv-03951-RBM-DEB, is assigned to District Judge Ruth Bermudez Montenegro and Magistrate Judge Daniel E. Butcher. The allegations are untested and remain unproven; the company has not been found liable for any wrongdoing.
What the claim alleges
The lawsuit centres on two items marketed to parents: CeraVe Baby Healing Ointment and CeraVe Baby Eczema Cream. According to the filing, each baby-branded product is materially identical in formulation to a corresponding non-baby CeraVe product. The complaint states that both healing ointments contain 46.5% petrolatum, and that both eczema creams contain 1% colloidal oatmeal alongside the same inactive ingredients and usage directions. On that basis, the plaintiff contends, the baby packaging commands a higher price without offering any meaningfully different product. These are allegations only and have not been established.
The pricing at issue
Price is the crux of the dispute. The complaint asserts that the baby eczema cream costs more per ounce than the standard version, and that the three-ounce baby healing ointment carried a premium of 30% or more at some retailers. The plaintiff argues that reasonable consumers, and parents in particular, may pay extra in the belief that a baby-specific product is formulated differently or more gently, when the underlying composition is said to be the same.
Legal basis and relief sought
The action advances several California causes of action: alleged breaches of the state's Unfair Competition Law and False Advertising Law, a claimed violation of the Consumers Legal Remedies Act, negligent misrepresentation, and unjust enrichment. The proposed class is defined as California purchasers who bought either product within the four years preceding the filing, and the amount in controversy is said to exceed $5 million. The plaintiff seeks class-wide damages, with injunctive relief also flagged as a likely point of contention. The case was filed on 9 July 2026 by the law firm Fitzgerald Monroe Flynn PC. At the time of reporting, no response or defence from L'Oréal had been recorded, and none of the claims has been adjudicated.
Wider implications for in-house counsel
For in-house legal teams, the case is a reminder that product-line segmentation, where a specialist or premium variant sits beside a standard equivalent, can attract scrutiny where the two share the same active and inactive ingredients. Marketing that implies a distinct formulation, combined with a price differential, may invite consumer-protection claims regardless of the product's actual safety or efficacy. Counsel advising consumer brands may wish to review how differentiated labelling maps to genuine formulation differences, to ensure substantiation files support any implied claims, and to confirm that pricing strategies across sibling products can withstand a false-advertising challenge. The outcome remains to be seen, and the allegations should be treated as unproven pending resolution.
